📈 Live Market Tracking
AI-Powered NSE Corporate Announcements Analysis
Thyrocare Updates Insider Trading Code of Conduct for Designated Persons
Thyrocare Technologies has amended its Code of Conduct to Regulate, Monitor and Report Trading by Designated Persons (PIT Code) following a board meeting on January 28, 2026. The revised code strictly defines 'Designated Persons' and 'Immediate Relatives' to prevent the misuse of Unpublished Price Sensitive Information (UPSI). It covers promoters, directors, and senior employees up to two levels below the CEO, including those in material subsidiaries. This update ensures the company remains compliant with the latest SEBI (Prohibition of Insider Trading) Regulations.
Key Highlights
Board approved the amended PIT Code on January 28, 2026, to align with SEBI regulations.
Code applies to employees up to two levels below the CEO and those in material subsidiaries with a 10% turnover/net worth threshold.
Defines 'Material Financial Relationship' as transactions involving 25% or more of a Designated Person's annual income.
Introduces an 'Insider Trading Compliance Tool' to automate the monitoring and reporting of trades by insiders.
💼 Action for Investors
This is a routine regulatory update focused on corporate governance and requires no specific action from shareholders. It reflects the company's commitment to maintaining transparency and preventing insider trading.
Thyrocare Q3 FY26 Results: Consolidated PAT Jumps 47% YoY to ₹27.9 Cr; Revenue Up 18%
Thyrocare Technologies reported a strong performance for Q3 FY26, with consolidated revenue growing 18% YoY to ₹195.5 crore. The company's profitability saw a significant boost as Reported EBITDA rose 38% YoY to ₹57.6 crore and Profit After Tax (PAT) surged 47% to ₹27.9 crore. Operational metrics remained robust with a 22% increase in tests conducted (49.6 million) and a 14% rise in patient volume. While the radiology segment saw a 7% revenue decline due to strategic exits from non-profitable centers, the core pathology business and partnership segments (up 39%) drove overall growth.
Key Highlights
Consolidated Revenue increased 18% YoY to ₹195.53 crore, driven by 20% growth in standalone pathology.
Reported EBITDA grew 38% YoY to ₹57.64 crore, with margins expanding from 25% to 29%.
Net Profit (PAT) surged 47% YoY to ₹27.91 crore; excluding exceptional items, PAT grew 80% to ₹34.07 crore.
Operational volume reached 49.6 million tests (+22% YoY) and 4.5 million patients (+14% YoY).
Partnership revenue grew by 39% YoY, while the active franchisee base expanded by 12% to approximately 10,300.
💼 Action for Investors
The company demonstrates strong operational leverage and volume-led growth in its core pathology segment. Investors should maintain a positive outlook given the margin expansion and robust partnership growth, while monitoring the impact of the new brand ambassador on retail market share.
Thyrocare Q3 FY26 Results: PAT Surges 47% YoY to ₹27.91 Cr, Revenue Up 18%
Thyrocare Technologies reported a robust Q3 FY26 with consolidated revenue growing 18% YoY to ₹195.53 crore, primarily driven by a 20% growth in the pathology segment. Profit After Tax (PAT) jumped 47% YoY to ₹27.91 crore, while EBITDA increased by 38% YoY to ₹57.64 crore, reflecting strong operational efficiency. The company processed a record 49.6 million tests, marking a 22% YoY volume growth. Additionally, partnership revenue, including PharmEasy, saw a significant 39% YoY increase, further strengthening its market position.
Key Highlights
Consolidated revenue grew 18% YoY to ₹195.53 crore, led by 20% growth in Pathology.
PAT surged 47% YoY to ₹27.91 crore; EBITDA rose 38% YoY to ₹57.64 crore.
Test volumes increased by 22% YoY to 49.6 million tests processed in Q3.
Partnership revenue (including PharmEasy) recorded robust 39% YoY growth.
Achieved Six Sigma quality standards with complaints reduced to 3.2 per million tests.
💼 Action for Investors
Investors should view these results positively as the company demonstrates strong volume growth and margin expansion. The significant growth in partnership revenue and operational benchmarks suggests a sustainable competitive advantage in the diagnostic space.
Thyrocare Q3 FY26 Net Profit Rises 37% YoY to ₹26.15 Cr; Revenue Up 20%
Thyrocare Technologies reported a strong performance for the quarter ended December 31, 2025, with revenue from operations growing 19.6% YoY to ₹182.48 crore. Net profit increased by 36.9% YoY to ₹26.15 crore, even after accounting for an exceptional charge of ₹5.97 crore related to new labor code compliance and capital restructuring. The company successfully executed a 2:1 bonus issue during the quarter, which resulted in the allotment of over 10.61 crore new shares. For the nine-month period, the company has shown robust growth with a net profit of ₹105.23 crore compared to ₹73.96 crore in the previous year.
Key Highlights
Revenue from operations increased 19.6% YoY to ₹182.48 crore from ₹152.55 crore.
Net Profit grew 36.9% YoY to ₹26.15 crore; 9M FY26 profit stands at ₹105.23 crore.
Exceptional item of ₹5.97 crore includes ₹4.01 crore for gratuity adjustments under New Labour Codes.
Successfully completed a 2:1 bonus share allotment on December 1, 2025, increasing paid-up capital to ₹159.16 crore.
Restated Basic EPS for the quarter stands at ₹1.64 compared to ₹1.18 in the year-ago period.
💼 Action for Investors
Investors should take note of the strong double-digit growth in both revenue and profitability, indicating improved operational efficiency. The completion of the bonus issue and the one-time nature of the labor code impact suggest a clean slate for future earnings growth.
Thyrocare Appoints Madhuri Dixit as Brand Ambassador to Drive Preventive Healthcare Awareness
Thyrocare Technologies has onboarded legendary actor Madhuri Dixit as its brand ambassador to strengthen its position in the preventive healthcare segment. The company aims to leverage her mass appeal to encourage routine health check-ups across its 10,000+ franchise network. In Q2FY26, Thyrocare processed over 53.3 million diagnostic investigations, demonstrating significant operational scale. This marketing push is intended to drive volume growth and improve brand recall in a highly competitive diagnostic market.
Key Highlights
Onboarded Madhuri Dixit as Brand Ambassador to boost brand trust and visibility across India.
Processed 53.3 million+ diagnostic and screening investigations in Q2FY26.
Operates an extensive network with a quarterly active franchise count of 10,000+.
Strategic focus on shifting consumer behavior from reactive treatment to proactive health management.
💼 Action for Investors
Investors should monitor if this branding push translates into higher retail volumes and B2C market share in upcoming quarters. The move reinforces Thyrocare's strategy to lead through high-volume, affordable diagnostics.